Navigation Links
BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
Date:9/24/2008

REHOVOT, Israel, September 24 /PRNewswire-FirstCall/ -- BioView Ltd, (TASE: BIOV) from Rehovot, Israel, reported today results of its internal clinical trial of the non-invasive diagnostic test under development for early detection of lung cancer.

In the trial a total of 76 sputum samples were collected from four groups of patients:

1. Healthy individuals that never smoked

2. Heavy smokers with no signs of lung cancer

3. Early stage lung cancer patients (Stage 1)

4. Advanced stage lung cancer patients

The sputum samples were blindly scanned and analyzed morphologically and genetically, with fluorescent probes exclusively licensed to BioView, on BioView's automated Duet scanning station by Company personnel. The results of the test were classified as "Normal", i.e. no cancer detected and "Abnormal", i.e. Cancer detected. These results were then compared to the actual data received from the hospital of the patients' condition.

The samples included 32 cases of lung cancer patients (about half of them early stage patients) and 44 samples taken from people with no clinical evidence of lung cancer. Thirty one of the thirty two (96.9%) sick patients were correctly diagnosed as "Abnormal" and thirty six of forty four (about 82%) healthy people were correctly diagnosed as "Normal".

Project leader, Dr. Michal Daniely says:"We have gained great confidence in this test as we see a direct relationship between our results and the clinical status of the patients".

Dr. Opher Shapira, BioView's CEO commented: "We are extremely pleased with the results; the specificity and sensitivity in this test are better than other non-invasive tests presently available for early lung cancer detection. We are accelerating our development efforts to improve these results as well as to increase our sample size and to include other laboratories in the clinical trials."

BioView lung cancer test in based on morphological
'/>"/>

SOURCE BioView Ltd
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
2. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
3. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
4. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
5. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
6. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
7. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
10. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... 2 AlloSource, one of the nation,s...ft tissue allografts for use in surgical procedure...ar bone growth substitutes, today announced its sp...oat rider aboard the annual Donate Life float in t...;. Manuel Salazar, a 29-year-old quadruple ampute...
(Date:12/2/2009).... 2 American Scientific...), announces that the Disintegrator Plus(TM), the ...device (NDD), is in its first production run for A...nt demand for home injection prescription drug use...g of the SB 486 which requires Californian,s to ...
(Date:12/2/2009)...W YORK, Dec. 2 Interleuk...ne Medical Center announced findings from a study ... the genetics of osteoarthritis have been publishe...nnals of Rheumatic Diseases and is available at h...df . Results from the study highlight importan...
Breaking Medicine Technology:AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 3World's Only FDA Approved Home Needle Destruction Device is in Production 2World's Only FDA Approved Home Needle Destruction Device is in Production 3Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 2Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 3Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 4Press conference schedule announced for TCT 2009 55559 1Press conference schedule announced for TCT 2009 55559 2Gene variation is major genetic determinant of psoriasis 55556 1Gene variation is major genetic determinant of psoriasis 55556 2Gene variation is major genetic determinant of psoriasis 55556 3Researchers report gene associated with language speech and reading disorders 9718 1Researchers report gene associated with language speech and reading disorders 9718 2
...in Poor Risk Frontline Elderly AML and in Combinat... , --Conference Call Scheduled for Tuesday, De...esults in AML-- , , SAN FRANCISCO , Dec. 7...today announced the presentation of new data from ... company,s novel drug candidate, voreloxin, shows ...
...uality of care for patients with sickle cell disea...nted at a press conference on Saturday, December 6...the American Society of Hematology in San Francisc... help determine stroke risk in children with sickl...ffects of long-term hydroxyurea use in adult patie...
Other Medicine Technology:Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 2Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 3Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 4Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 5Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 6Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 7Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 8Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 9
(Date:12/2/2009)... N.Y., Dec. 2 Researche...gs in blood cancer research at the annual American...eans December 4-8, 2009. ,, Throughout the ASH...LLS) experts, including Chief Medical Officer Bart...tient Services Hildy Dillon, and Vice President, R...
(Date:12/2/2009)... Dec. 2 Independence Blue Cross (I...ct with Lincoln Financial Group. IBC will be the p...ely 10,000 Lincoln Financial Group employees, reti...Lincoln plan offerings will include the PPO option...now I speak for all of us at Independence Blue Cro...
(Date:12/2/2009)...i loves sports. An avid tennis player and golfer, ... agent became increasingly frustrated over time as...ative eye disorder. Unable to return the tennis ba... prospect of a corneal transplant to restore his v...alboni discovered an alternative treatment. He rec...
(Date:12/2/2009)...National Pen ( www.pens.com ), a worldwide leading... is giving away 10,000 free business card pens. ,...-- National Pen ( www.pens.com ), a worldwide lead...it is giving away 10,000 free business card pens. ...ness that no other company in the industry can do,...
(Date:12/2/2009)...On Sunday, more than 900 runners and walkers from ...nish line at the Rock ‘n’ Roll Las Veg...er $3.2 million for the Crohn,s & Colitis Foun... Team Challenge (www.ccteamchallenge). As the offi... research, education, and support initiatives to b...
Breaking Medicine News(10 mins):Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3Health News:Brandeis studies evaluate visionary approach to improving eyesight 2Health News:National Pen Giving Away 10,000 Business Card Pens 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 3Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 4
.... Miller and team from Virginia Polytechnic Instit... content declines// significantly in men after one... CABG involves the removal of blocks in more tha...years who have undergone this surgery were studied...
... than the hottest month in the last 100 years. Th...//the microorganism cryptosporidium, in this par...ear of the parasitic outbreak compare with just 52.... 'We usually estimate that about 10 per cent ...
... than diabetes say researchers. If you are a woman...ing cancer. // Researchers from the Department...versity Hospital in Sweden, led by Dr. Par Stattin...60. The research named the V?sterbotten Inter...
...ing to the Internet to find information, important... in the sheer avalanche of facts// now available o...n the top 30 Google search results. New rese...y attention not only to the quality of their sites...
...d to be in the centre of a health controversy invo...ent had requested people //who ate at Wagamama res... seek the help of a doctor if they develop fever, ...untry. Dr Penelope Hutchinson, spokesperson for Qu...
...ession of the International Association for Dental...ing that they have developed an effective program ...orsythKids, is an innovative school-based cavity p...olled in the program, one round of treatment reduc...
Other Medicine News:Health News:Women – watch Your Fat and Sugar Intakes to Keep Cancer at Ba 2Health News:Key Science Web Sites Buried in Information Avalanche 2Health News:Forsyth Scientists Wiping Out Tooth Decay Through School-based Cavities Prevention Program 2
VascoTip P 9/60 PU S
VascoTip E 9/60 PU M
VascoTip P 9/60 S
VascoTip E 9/60 M
Medicine Products: